Gennao Bio
PrivateLast Round
Series B
Dec 8, 2022
Total Funding Raised
$56M
Company Overview
Gennao Bio operates in Healthcare & Life Sciences and is based in Hopewell, New Jersey. Its latest recorded funding round was a Series B round in December 2022.
Gennao Bio is a biotechnology company that develops targeted nucleic acid therapeutics using its proprietary gene monoclonal antibody (GMAB) platform technology to treat oncology and rare skeletal muscle diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gennao Bio Comparables
Compare Gennao Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Patrys Limited | 76% | |
| Novartis | 76% | |
| Tallac Therapeutics | 73% |
For institutional investors. Book with your work email.
Gennao Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 8, 2022 | ||||
| Series A Extension | Dec 22, 2021 | ||||
| Series A | May 10, 2021 |
For institutional investors. Book with your work email.
Gennao Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series A |
| CureDuchenne Ventures | Series B, Series A Extension |
| GordonMD Global Investments | Series B |
| OrbiMed | Series B, Series A |
| Logos Capital | Series B, Series A |
| Citadel | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 10, 2021
$40M round led by Logos Capital and OrbiMed.
For institutional investors. Book with your work email.
Gennao Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gennao Bio's valuation, stock price, and market status.
Is Gennao Bio a public or private company?
Gennao Bio is a private company.
What is the current stock price of Gennao Bio?
Gennao Bio is a private company, so its shares have no public market price. Caplight tracks Gennao Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gennao Bio worth (valuation)?
Valuation information for Gennao Bio is not publicly available.
Can I buy Gennao Bio stock?
Gennao Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gennao Bio's last funding round?
Gennao Bio's most recent funding round was Series B on December 8, 2022.
Who are the main investors in Gennao Bio?
Key investors in Gennao Bio include CureDuchenne Ventures, OrbiMed, Logos Capital.
Will Gennao Bio IPO soon?
No public IPO plans have been announced for Gennao Bio.
How can I track Gennao Bio secondary market activity?
Caplight tracks bids, offers, and trades in Gennao Bio's shares on secondary markets.